The Federal Trade Commission asked a federal judge to hold “pharma bro” Martin Shkreli in contempt for failing to provide the agency with information needed to determine whether he is violating an order that permanently banned him from working in the pharmaceutical industry.
In a motion filed federal court in New York, the FTC and seven state regulators argued that Shkreli has failed to comply with their requests to provide documents and sit for an interview as part of their investigation into whether he violated the ban by forming and operating his new company, which is called Druglike Inc.
According to its website, the company claims it can use a software platform for “democratizing the access, costs and rewards of early-stage drug discovery.” In a press release issued last July, Druglike maintained it is a “blockchain/Web3 software company and not a pharmaceutical company. Druglike is not engaged in pharmaceutical research or drug development.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect